Palisade Bio (PALI) Competitors $1.95 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.95 0.00 (-0.21%) As of 05/22/2026 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PALI vs. ABCL, AVBP, SEPN, CALT, and WVEShould you buy Palisade Bio stock or one of its competitors? MarketBeat compares Palisade Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Palisade Bio include AbCellera Biologics (ABCL), ArriVent BioPharma (AVBP), Septerna (SEPN), Calliditas Therapeutics AB (publ) (CALT), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry. PALI vs. ABCLPALI vs. AVBPPALI vs. SEPNPALI vs. CALTPALI vs. WVEHow does Palisade Bio compare to AbCellera Biologics?Palisade Bio (NASDAQ:PALI) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations. Do analysts prefer PALI or ABCL? Palisade Bio presently has a consensus target price of $10.20, suggesting a potential upside of 423.08%. AbCellera Biologics has a consensus target price of $7.80, suggesting a potential upside of 50.00%. Given Palisade Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Palisade Bio is more favorable than AbCellera Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88AbCellera Biologics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has more risk & volatility, PALI or ABCL? Palisade Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market. Is PALI or ABCL more profitable? Palisade Bio has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Palisade Bio's return on equity.Company Net Margins Return on Equity Return on Assets Palisade BioN/A -36.79% -34.34% AbCellera Biologics -181.75%-14.86%-10.62% Do insiders & institutionals hold more shares of PALI or ABCL? 11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media prefer PALI or ABCL? In the previous week, Palisade Bio had 7 more articles in the media than AbCellera Biologics. MarketBeat recorded 8 mentions for Palisade Bio and 1 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.95 beat Palisade Bio's score of 0.67 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Overall Sentiment Palisade Bio Positive AbCellera Biologics Positive Which has preferable earnings and valuation, PALI or ABCL? Palisade Bio has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalisade Bio$250K1,353.92-$16.78M-$1.01N/AAbCellera Biologics$75.13M21.14-$146.41M-$0.48N/A SummaryPalisade Bio beats AbCellera Biologics on 9 of the 16 factors compared between the two stocks.How does Palisade Bio compare to ArriVent BioPharma?ArriVent BioPharma (NASDAQ:AVBP) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk. Do analysts prefer AVBP or PALI? ArriVent BioPharma currently has a consensus target price of $43.13, suggesting a potential upside of 61.34%. Palisade Bio has a consensus target price of $10.20, suggesting a potential upside of 423.08%. Given Palisade Bio's higher possible upside, analysts clearly believe Palisade Bio is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.91Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 Which has stronger earnings & valuation, AVBP or PALI? Palisade Bio has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$166.31M-$3.47N/APalisade Bio$250K1,353.92-$16.78M-$1.01N/A Is AVBP or PALI more profitable? Palisade Bio's return on equity of -36.79% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -48.98% -45.44% Palisade Bio N/A -36.79%-34.34% Do institutionals & insiders hold more shares of AVBP or PALI? 9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by insiders. Comparatively, 0.1% of Palisade Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to AVBP or PALI? In the previous week, Palisade Bio had 7 more articles in the media than ArriVent BioPharma. MarketBeat recorded 8 mentions for Palisade Bio and 1 mentions for ArriVent BioPharma. Palisade Bio's average media sentiment score of 0.67 beat ArriVent BioPharma's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media. Company Overall Sentiment ArriVent BioPharma Neutral Palisade Bio Positive Which has more volatility and risk, AVBP or PALI? ArriVent BioPharma has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. SummaryPalisade Bio beats ArriVent BioPharma on 11 of the 15 factors compared between the two stocks.How does Palisade Bio compare to Septerna?Palisade Bio (NASDAQ:PALI) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations. Do insiders & institutionals hold more shares of PALI or SEPN? 11.8% of Palisade Bio shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by company insiders. Comparatively, 4.3% of Septerna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, PALI or SEPN? Palisade Bio has higher earnings, but lower revenue than Septerna. Septerna is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalisade Bio$250K1,353.92-$16.78M-$1.01N/ASepterna$45.95M27.82-$48.88M-$0.81N/A Which has more risk & volatility, PALI or SEPN? Palisade Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Septerna has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market. Is PALI or SEPN more profitable? Palisade Bio has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Palisade Bio's return on equity.Company Net Margins Return on Equity Return on Assets Palisade BioN/A -36.79% -34.34% Septerna -49.88%-12.72%-8.87% Do analysts prefer PALI or SEPN? Palisade Bio presently has a consensus price target of $10.20, suggesting a potential upside of 423.08%. Septerna has a consensus price target of $43.13, suggesting a potential upside of 52.06%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Septerna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88Septerna 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80 Does the media refer more to PALI or SEPN? In the previous week, Palisade Bio had 8 more articles in the media than Septerna. MarketBeat recorded 8 mentions for Palisade Bio and 0 mentions for Septerna. Palisade Bio's average media sentiment score of 0.67 beat Septerna's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the media. Company Overall Sentiment Palisade Bio Positive Septerna Neutral SummaryPalisade Bio beats Septerna on 9 of the 16 factors compared between the two stocks.How does Palisade Bio compare to Calliditas Therapeutics AB (publ)?Palisade Bio (NASDAQ:PALI) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations. Which has better earnings and valuation, PALI or CALT? Palisade Bio has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalisade Bio$250K1,353.92-$16.78M-$1.01N/ACalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85N/A Is PALI or CALT more profitable? Palisade Bio has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Palisade Bio's return on equity of -36.79% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Palisade BioN/A -36.79% -34.34% Calliditas Therapeutics AB (publ) -30.18%-212.04%-27.96% Does the media prefer PALI or CALT? In the previous week, Palisade Bio had 8 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 8 mentions for Palisade Bio and 0 mentions for Calliditas Therapeutics AB (publ). Palisade Bio's average media sentiment score of 0.67 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Palisade Bio is being referred to more favorably in the media. Company Overall Sentiment Palisade Bio Positive Calliditas Therapeutics AB (publ) Neutral Which has more risk and volatility, PALI or CALT? Palisade Bio has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Do institutionals & insiders believe in PALI or CALT? 11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 0.1% of Palisade Bio shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate PALI or CALT? Palisade Bio presently has a consensus price target of $10.20, suggesting a potential upside of 423.08%. Given Palisade Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Palisade Bio is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryPalisade Bio beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks.How does Palisade Bio compare to WAVE Life Sciences?WAVE Life Sciences (NASDAQ:WVE) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership. Do analysts rate WVE or PALI? WAVE Life Sciences currently has a consensus price target of $27.25, indicating a potential upside of 327.12%. Palisade Bio has a consensus price target of $10.20, indicating a potential upside of 423.08%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts plainly believe Palisade Bio is more favorable than WAVE Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score WAVE Life Sciences 1 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.87Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 Is WVE or PALI more profitable? Palisade Bio has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Palisade Bio's return on equity of -36.79% beat WAVE Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets WAVE Life Sciences-255.70% -56.76% -42.80% Palisade Bio N/A -36.79%-34.34% Does the media prefer WVE or PALI? In the previous week, WAVE Life Sciences had 4 more articles in the media than Palisade Bio. MarketBeat recorded 12 mentions for WAVE Life Sciences and 8 mentions for Palisade Bio. Palisade Bio's average media sentiment score of 0.67 beat WAVE Life Sciences' score of 0.07 indicating that Palisade Bio is being referred to more favorably in the news media. Company Overall Sentiment WAVE Life Sciences Neutral Palisade Bio Positive Which has preferable earnings and valuation, WVE or PALI? Palisade Bio has lower revenue, but higher earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWAVE Life Sciences$42.73M28.73-$204.38M-$1.06N/APalisade Bio$250K1,353.92-$16.78M-$1.01N/A Do institutionals and insiders have more ownership in WVE or PALI? 89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 24.3% of WAVE Life Sciences shares are owned by insiders. Comparatively, 0.1% of Palisade Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, WVE or PALI? WAVE Life Sciences has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. SummaryPalisade Bio beats WAVE Life Sciences on 12 of the 17 factors compared between the two stocks. Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PALI vs. The Competition ExportMetricPalisade BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$338.48M$3.37B$6.45B$12.34BDividend YieldN/A2.26%2.76%5.28%P/E Ratio-1.9318.7421.2225.65Price / Sales1,353.92323.98553.9286.28Price / CashN/A125.1743.4956.67Price / Book2.677.0910.377.14Net Income-$16.78M$24.45M$3.57B$335.98M7 Day Performance7.73%5.45%6.01%3.56%1 Month Performance-6.25%2.43%3.52%2.54%1 Year Performance141.64%62.98%34.13%35.05% Palisade Bio Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PALIPalisade Bio2.299 of 5 stars$1.95flat$10.20+423.1%+141.6%$338.48M$250KN/A10Analyst RevisionGap UpABCLAbCellera Biologics3.0673 of 5 stars$4.05-2.6%$7.80+92.6%+164.0%$1.24B$75.13MN/A500AVBPArriVent BioPharma2.3889 of 5 stars$26.15-3.3%$42.78+63.6%+31.0%$1.22BN/AN/A40Analyst ForecastSEPNSepterna2.8663 of 5 stars$26.51+0.8%$43.13+62.7%+208.6%$1.20B$45.95MN/AN/ACALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60BN/A180 Related Companies and Tools Related Companies ABCL Alternatives AVBP Alternatives SEPN Alternatives CALT Alternatives WVE Alternatives AVLN Alternatives MLTX Alternatives MPLT Alternatives OLMA Alternatives HROW Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PALI) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
